<PAGE>
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 22, 1995
-----------------------------------------------------------------
Rhone-Poulenc Rorer Inc.
-----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Pennsylvania 1-5851 23-1699163
--------------------------------------------------------------------------
(State or other juris- (Commission (IRS Employer
diction of incorporation) File Number) Identification No.)
500 Arcola Road, Collegeville, PA 19426
---------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (610)454-8000
----------------------
------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
<PAGE>
Item 5. Other Events
- -------------------------------
As announced in the attached press release, on February 22, 1995, Rhone-
Poulenc Rorer's Armour Pharmaceutical Company subsidiary and Behringwerke AG,
a subsidiary of Hoechst AG, signed an agreement to form a global joint
venture dedicated to the plasma proteins business. Under the terms of the
agreement, both companies will contribute to the joint venture all the assets
of their respective plasma operations in exchange for a 50% interest in the
new entity. The agreement is subject to U.S. and European regultory approvals.
Item 7. Exhibits
- -----------------------------
(c) Exhibit 20 - Armour Pharmaceutical Company and Behringwerke AG press
release dated February 23, 1995.
2
<PAGE>
<PAGE>
SIGNATURES
----------------------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RHONE-POULENC RORER INC.
----------------------------------------
(registrant)
Dated: March 8, 1995 By: /s/Richard B. Young
--------------------------------------------
Richard B. Young
Vice President and Secretary
3
<PAGE>
<PAGE>
EXHIBIT INDEX
-----------------------
(20) Armour Pharmaceutical Company and Behringwerke AG press release dated
February 23, 1995.
4
EXHIBIT 20
A(company insignia) BEHRING(company insignia)
ARMOUR Behringwerke AG
PHARMACEUTICAL Postfach 1140
COMPANY FOR IMMEDIATE RELEASE D 35001 Marburg
Collegeville, PA 19426
ARMOUR AND BEHRINGWERKE TO CREATE A JOINT VENTURE.
Pennsylvania, USA and Marburg, Germany - February 23, 1995 - Armour
Pharmaceutical Company, a subsidiary of Rhone-Poulenc Rorer Inc. (NYSE:RPR),
and Behringwerke AG, a subsidiary of Hoechst AG, announced the signing of an
agreement to form a joint venture in the highly competitive field of plasma
proteins.
Under the terms of the agreement, both companies will contribute to the joint
venture all of the assets of their respective plasma operations in exchange
for a one-half equity interest in a new entity.
A priority of the joint venture would be to increase the availability of
innovative products through its enhanced capacity to invest in research and
development. Armour and Behringwerke have complementary product lines, that
if combined, would provide a broad range of life-saving therapies to patients
throughout the world. The companies also complement each other
geographically as Armour has a strong presence in the United States, while
Behringwerke is principally in Europe and Japan.
Over the last decade, Armour and Behringwerke have both developed important
product and technology innovations in the plasma protein field. Both
companies also use liquid pasteurization for viral inactivation and have
active programs in recombinant and gene therapy research.
The agreement is subject to regulatory approval by agencies of the United
States government and the European Union.
Behringwerke is a global pharmaceutical company dedicated to the discovery,
development, manufacturing and marketing of plasma proteins, vaccines and
diagnostic products.
Armour is a global pharmaceutical company dedicated to the discovery,
development, manufacturing and marketing of plasma proteins.
Contacts:
Armour Behringwerke AG:
Beth Leahy: (610)454-3879 Wolfgang Faust: (49)6421 39 4189
Catherine LeLouarn: (33)1.40.91.4168
5
